Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced preclinical results that further support varlilumab’s expansion into combination studies with PD-1 inhibitors.
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $43, after the company announced the initiation …
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in …
As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with …
In a research report issued today, Cowen analyst Boris Peaker reiterated an Outperform rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) and raised the price target from $26 to …
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of …
